Foreign vaccine firm faces administrative disposition for false advertisements

Published: 2004-11-01 07:00:00

Updated: 2004-11-01 07:00:00

Amid growing controversy over the efficacy of imported influenza vaccine, the Korea Food and Drug Administration said on October 27 that it is considering taking administrative measures to GlaxoSmithKline (GSK) for falsely advertising its influenza vaccine, Fluarix, as more effective than others ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK